Rachel Jankowitz, MD
Hematology & Oncology · Philadelphia, PANPI 1104027218
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (39.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Merck at 39.1% of the total. Reporting peaked in 2019 at $1,746 and has fallen 71.9% since, to $491 in 2025.
Across 19 payments — averaging $202.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2K
- AstraZeneca$1K
- Pfizer$461
- Gilead$255
- Stryker$200
- Medtronic$150
- plus $260 from 2 others
Across 35 payments — averaging $27,387 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$752K
- AstraZeneca$107K
- Merck$61K
- Jazz Pharmaceuticals Inc.$38K
What the payments were for
- Consulting fees$1,50039%
- Speaking & faculty fees$76920%
- Travel & lodging$1735%
- Food & beverage$1,38536%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 1 | $1,500 |
| AstraZeneca | 5 | $1,013 |
| Pfizer | 4 | $461 |
| Gilead | 3 | $255 |
| Stryker | 2 | $200 |
| Medtronic | 2 | $150 |
| Novartis | 1 | $137 |
| Stemline Therapeutics Inc. | 1 | $123 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,838 in reported general payments places this provider in the 60th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 147 | $3,517 |
| Letrozole | 25 | $535 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Philadelphia
- Henry FungPhiladelphia$730K
- Charu AggarwalPhiladelphia$541K
- Corey LangerPhiladelphia$492K
- Ankur ParikhPhiladelphia$329K
- Catherine LaiPhiladelphia$281K
- Stephen SchusterPhiladelphia$218K
- Keith PratzPhiladelphia$173K
- David PorterPhiladelphia$140K
- Adam BinderPhiladelphia$136K
- Marcela MausPhiladelphia$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.